Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
Front Immunol. 2019 Apr 2;10:604. doi: 10.3389/fimmu.2019.00604. eCollection 2019.
In oncology, the "abscopal effect" refers to the therapeutic effect on a distant tumor resulting from the treatment of local tumor (e. g., ablation, injection, or radiation). Typically associated with radiation, the abscopal effect is thought to be mediated by a systemic antitumor immune response that is induced by two concurrent changes at the treated tumor: (1) the release of tumor antigens and (2) the exposure of damage-associated molecular patterns. Therapies that produce these changes are associated with immunogenic cell death (ICD). Some interventions have been shown to cause an abscopal effect without inducing the release of tumor antigens, suggesting that release of tumor antigens at baseline plays a significant role in mediating the abscopal effect. With tumor antigens already present, therapies that target activation of APCs alone may be sufficient to enhance the abscopal effect. Here, we discuss two therapies targeted at APC activation, TLR9 and CD40 agonists, and their use in the clinic to enhance the abscopal effect.
在肿瘤学中,“远隔效应”是指对局部肿瘤(如消融、注射或放疗)治疗导致的远处肿瘤的治疗效果。远隔效应通常与放疗有关,被认为是由治疗肿瘤时同时发生的两种变化介导的全身性抗肿瘤免疫反应:(1)肿瘤抗原的释放;(2)损伤相关分子模式的暴露。产生这些变化的治疗方法与免疫原性细胞死亡(ICD)有关。一些干预措施已被证明可在不诱导肿瘤抗原释放的情况下引起远隔效应,这表明基线时肿瘤抗原的释放在介导远隔效应中起着重要作用。由于已经存在肿瘤抗原,仅靶向 APC 激活的治疗方法可能足以增强远隔效应。在这里,我们讨论了两种针对 APC 激活的治疗方法,即 TLR9 和 CD40 激动剂,以及它们在临床上用于增强远隔效应的应用。